Tolerability and safety of rituximab (MabThera®)

This publication has 106 references indexed in Scilit:

• Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
  Blood, 2005
• Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
  Clinical Cancer Research, 2004
• Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma
  Seminars in Oncology, 2003
• The mechanisms of action of rituximab in the elimination of tumor cells
  Seminars in Oncology, 2003
• Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia
  Leukemia & Lymphoma, 2003
• Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
  Blood, 2002
• Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab
  American Journal of Hematology, 2001
• CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB
  British Journal of Haematology, 1999
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• OKT3 first-dose reaction: Association with T cell subsets and cytokine release
  Kidney International, 1991